菌 (Faecalibacterium prausnitzii) 通过调节胆酸代谢和调节FXR信号来改善DSS诱导的结肠炎
Pingnan Zhang1, Saifei Xu1, Na Li1
1Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
Digestive diseases and sciences
|July 5, 2025
概括
菌 (Faecalibacterium prausnitzii) 通过改变肠道细菌和胆酸来缓解性结肠炎,激活FXR通路以减少炎症和修复肠道. 这突显了微生物群-胆酸-FXR轴作为IBD的潜在治疗点.
科学领域:
- 胃肠道学和微生物学
- 炎症性肠道疾病研究研究
- 肠道微生物组和代谢学
背景情况:
- 性结肠炎 (UC) 是一个日益严重的全球健康问题.
- 杆菌 (F. prausnitzii) 具有抗炎性质.
- 结肠炎中F.prausnitzii,肠道微生物群和胆酸代谢之间的联系机制尚未完全理解.
研究的目的:
- 研究F.prausnitzii对大肠炎的治疗作用.
- 阐明涉及肠道微生物群和胆酸调节的潜在机制.
- 为了确定Farnesoid X受体 (FXR) 信号通路的作用.
主要方法:
- 德克斯硫酸 (DSS) 诱导的大肠炎小鼠模型.
- 管理F. prausnitzii及其超级剂.
- 分析肠道微生物群组成 (16S rRNA测序) 和胆酸特征 (代谢学).
- 评估炎症标志物,肠道屏障完整性和FXR信号.
主要成果:
- F. prausnitzii调节了肠道微生物群和胆酸概况,增加了未结合和二次胆酸.
- 观察到FXR信号通路的激活,这对于F. prausnitzii的保护作用至关重要.
- F. prausnitzii促进了粘膜的修复,抑制了NLRP3炎症酶,并增强了屏障功能,部分是通过胆汁酸isoLCA.
结论:
- F.prausnitzii通过胆酸调节和FXR信号调节来缓解大肠炎.
- 微生物群-胆酸-FXR轴为炎症性肠病提供了一个有前途的治疗途径.
- 针对这种途径可以为UC提供新的治疗策略.
相关概念视频
01:17Chronic Bowel Disorders: Introduction
541
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
541
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
428
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
428
01:17Drugs for Treatment of Diarrhea-Predominant IBS
308
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
308
01:29Drugs for Treatment of Ulcerative Colitis in IBD
242
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
242
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
334
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
334
01:17Irritable Bowel Syndrome I: Introduction
395
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
395